argenex (ARGX) Expected to Announce Earnings on Thursday

argenex (NASDAQ:ARGX) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect argenex to post earnings of $6.05 per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

argenex Stock Performance

Shares of NASDAQ ARGX opened at $845.35 on Thursday. The firm has a market cap of $52.31 billion, a P/E ratio of 36.30, a PEG ratio of 0.73 and a beta of 0.37. The stock has a fifty day moving average price of $832.74 and a two-hundred day moving average price of $804.51. argenex has a 1 year low of $510.05 and a 1 year high of $934.62.

Wall Street Analyst Weigh In

ARGX has been the subject of several research reports. DZ Bank upgraded shares of argenex to a “strong-buy” rating in a research report on Friday, December 19th. TD Cowen raised their target price on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Piper Sandler lifted their price target on shares of argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Finally, Wedbush reaffirmed an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $986.78.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ARGX. AQR Capital Management LLC increased its holdings in argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after buying an additional 122 shares during the last quarter. NewEdge Advisors LLC increased its stake in shares of argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after purchasing an additional 73 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after purchasing an additional 50 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.